The Biotechnology & Pharmaceuticals company announced operating deficit in the fourth quarter of 2022

Revenues have tumbled at the company during the fourth quarter of 2022 earnings season

For the fiscal period closing December 31 2022 company profitability turned positive of $0.01 per share compare to $-0.14 a year before and earnings per share dropped by -99.63 % from $1.64 per share from the preceding financial reporting period.

Revenues faded by -37.649 % to $0.19 millions from $0.31 millions in the corresponding financial reporting period a year before and sequentially Revenue Tumbled by -49.218 % from $0.38 millions.

Aei Income And Growth Fund Xxi Limited Partnership Customers

Aei Income And Growth Fund Xxi Limited Partnership advance Rates, Profitability, PE

Shortfall In spite of Revenues elevation at in the financial fourth quarter of 2022

For the financial fourth quarter of 2022 Creative Media And Community Trust Corporation Losses have extended of $-0.39 per share compare to $-0.38 a year before and Income per Share improved from $-0.50 per share from the prior reporting season.

Revenue grew moderately by 2.957 % to $25.87 millions from $25.13 millions in the corresponding reporting season a year before and sequentially Revenues surged by 4.084 % from $24.85 millions.

Creative Media And Community Trust Corporation stock quotes, charts, profile

Creative Media And Community Trust Corporation Suppliers

Excellent result by the company during the fiscal fourth quarter of 2022

For the financial fourth quarter of 2022 company lost money of $-0.04 per share compare to $-0.08 a year ago and from $-0.04 per share from the prior reporting season.

Revenues rose admirably by 16.316 % to $2.15 millions from $1.85 millions in the same reporting season a year ago and sequentially Revenues surged by 3.909 % from $2.07 millions.

Aspira Women S Health Inc Competitors, Market Share

Aspira Women S Health Inc improvement Rates, Profitability, PE

Revenues receded in single digits, at the company all along the fiscal period ending December 31 2022

For the fourth quarter of 2022 earnings season company net profit per share plummeted by -44.5 % of $0.55 per share compare to $0.99 a year prior and profit plummeted by -55.19 % from $1.22 per share from the previous reporting period.

Revenues depreciated by -6.343 % to $8.80 millions from $9.40 millions in the same reporting period a year prior and sequentially Revenues fell by -26.514 % from $11.98 millions.

Quaint Oak Bancorp Inc Customers

Quaint Oak Bancorp Inc Suppliers

EPS Drops due to Weak Sales at the Socket Mobile Inc over the financial interval ending December 31 2022

In the financial interval ending December 31 2022 the company announced soft top and bottom-line, where reached zero gain and revenue by -15.427 % year on year. Revenue were to $5.17 millions compared to $6.11 millions eps at $0.00 in contrast to $0.09 in fourth quarter of 2021.

Socket Mobile Inc Competitors, Market Share

Socket Mobile Inc Revenue rise Rates

In the financial fourth quarter of 2022 operating shortfall reflected enhancement to $-30.002921 millions, at the Better Therapeutics Inc

The shareholders have not assumed any adjustments at the business all over the earnings season of the October to December 31 2022 period at the Better Therapeutics Inc . Yet, stockholders monitor the Medical Equipment & Supplies company's operating shortfall that was at $-8.322 millions, during the same period.

Better Therapeutics Inc Customers

Better Therapeutics Inc Suppliers

For the fiscal time-frame closing December 31 2022 Aptevo Therapeutics Inc decreased a loss per share of $-0.84 per share compare to $-1.28 a year ago and EPS improved from $-1.50 per share from the prior reporting season.

Revenues remained unchanged to $0.00 millions from $3.67 millions in the comparable reporting season a year ago and sequentially Revenues surged from $0.00 millions.

Aptevo Therapeutics Inc stock quotes, charts, profile

Aptevo Therapeutics Inc Suppliers

Shifting our appreciation to the fourth quarter of 2022 earnings season Candel Therapeutics Inc Deficit has extended at $-0.15 per share, relative to the earnings of $1.54 per share a year before reporting season, In the preceding reporting season the Biotechnology & Pharmaceuticals company realized $-0.30 per share.

Candel Therapeutics Inc Suppliers

Candel Therapeutics Inc Income Statement, Balance sheets, Cash Flow Statement

In the most recent fiscal period DBV reached zero gain at $0.00 per share, opposite of $0.00 per share a year prior financial reporting period, In the prior financial reporting period The company realized $0.00 per share.

Invesco Db G10 Currency Harvest Fund stock quotes, charts, profile

Invesco Db G10 Currency Harvest Fund Revenue improvement Rates